2025 United States Age-Related Mascular Degeneration Revenue Opportunities Report
Description
The 2025 United States Age-Related Mascular Degeneration Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) market in the United States are Regeneron Pharmaceuticals, F. Hoffmann-La Roche Ltd., Novartis AG, and Bayer AG. Regeneron, headquartered in New York, is a prominent biotech firm known for its leading AMD drug Eylea, widely used for wet AMD treatment. It invests heavily in drug development and has global operations enhancing AMD therapeutics. Roche, based in Switzerland, markets the FDA-approved drug Lucentis for neovascular AMD. Novartis and Bayer also have significant roles, continuously advancing drug pipelines and collaborating internationally to improve AMD therapies.
These companies dominate the U.S. AMD market with innovative treatments, including monoclonal antibodies and gene therapies targeting both wet and dry AMD forms. Their extensive research and clinical trials aim at slowing AMD progression and restoring vision. The market value, especially for wet AMD treatments, is rapidly growing, expected to hit billions by the late 2020s, propelled mainly by these leaders' efforts in expanding and refining therapeutic options.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) market in the United States are Regeneron Pharmaceuticals, F. Hoffmann-La Roche Ltd., Novartis AG, and Bayer AG. Regeneron, headquartered in New York, is a prominent biotech firm known for its leading AMD drug Eylea, widely used for wet AMD treatment. It invests heavily in drug development and has global operations enhancing AMD therapeutics. Roche, based in Switzerland, markets the FDA-approved drug Lucentis for neovascular AMD. Novartis and Bayer also have significant roles, continuously advancing drug pipelines and collaborating internationally to improve AMD therapies.
These companies dominate the U.S. AMD market with innovative treatments, including monoclonal antibodies and gene therapies targeting both wet and dry AMD forms. Their extensive research and clinical trials aim at slowing AMD progression and restoring vision. The market value, especially for wet AMD treatments, is rapidly growing, expected to hit billions by the late 2020s, propelled mainly by these leaders' efforts in expanding and refining therapeutic options.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
